aGCTs are clinical and molecular unique subtype of ovarian cancer, characterized by a pathognomonic somatic missense point mutation 402C->G (C134W) in the transcription factor fork head box protein L2 (FOXL2).[7] The FOXL2 402C->G mutation leads to increased proliferation and survival of granulosa cells, and promotes hormonal changes. This evidence concerns the gene FOXL2 and ovarian cancer.